Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tebotelimab - MacroGenics

Next Previous
Drug Profile

Tebotelimab - MacroGenics

Alternative Names: Anti-LAG-3 bispecific DART protein; MGD-013; PD-1 x LAG-3 bispecific DART molecule; PD-1 X LAG-3 DART

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; ZAI Lab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • No development reported Haematological malignancies; Solid tumours
  • Discontinued Biliary cancer; Cholangiocarcinoma; Endometrial cancer; Gastric cancer; Liver cancer; Malignant melanoma; Oesophageal cancer; Triple negative breast cancer

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (IV, Infusion)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Bulgaria (IV, Infusion)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Poland (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top